Providing Phase lll-ready radiolabelled antibody due diligence

Challenge A well-capitalized strategic investor looking to enter the radiopharmaceuticals market wanted to conduct clinical due diligence on a novel radioisotope-conjugated antibody designed to treat...
Learn More

Providing Rubidium-82 due diligence

Challenge Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the USA. One target company was developing a new...
Learn More

Radionucleotide imaging due diligence

Challenge A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Providing scientific and immunological mechanism of action due diligence for a big pharma client

Challenge A major pharma company needed scientific and immunology due diligence support on a novel cyclic peptide, targeting the complement cascade system.
Learn More

Providing pharmacovigilance due diligence of a Phase lll oncology program

Challenge A major pharmaceutical company asked us for support in the medical safety and pharmacovigilance due diligence and assessment of a Phase III in-licensing opportunity. The drug in question...
Learn More

Providing due diligence in neurology

Challenge A venture capital investor needed an assessment of the technical, regulatory and market risks in a neuroscience specialty pharma company developing a range of products through the 505...
Learn More

Assessing commercial viability of biosimilars

Challenge A European pharma company seeking to license a development-stage follow-on biologic needed to assess the commercial potential of a second-generation antibody against a validated oncology...
Learn More

Assessing an AAV gene therapy for an ophthalmic indication

Challenge: We were asked to conduct an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and the identification of key...
Learn More

In-licensing due diligence for a respiratory drug

Challenge A pharma company needed help conducting due diligence on an in-licensing/acquisition candidate for a Phase IIb respiratory drug.
Learn More

Assessment of a blood product

Challenge A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality check on the...
Learn More

Providing due diligence for an Alzheimer’s treatment

Challenge Our client, a major pension fund, was considering an investment in a Phase III neuroscience company, which was developing a small molecule to provide symptomatic relief of Alzheimer’s...
Learn More

Preparing an expert review paper

Challenge A venture-backed biotech company developing a clinical stage asset for the treatment of early-stage cancer was populating a data room and preparing for negotiations with a major pharma...
Learn More
Content not found